BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright lowered their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Price Performance

BLRX opened at $0.14 on Friday. The firm has a 50-day moving average price of $0.29 and a 200-day moving average price of $0.51. BioLineRx has a twelve month low of $0.14 and a twelve month high of $1.52. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The company has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.65 and a beta of 1.46.

Institutional Investors Weigh In On BioLineRx

Several hedge funds and other institutional investors have recently modified their holdings of BLRX. PVG Asset Management Corp bought a new position in shares of BioLineRx in the second quarter valued at approximately $70,000. Atria Investments Inc boosted its holdings in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC purchased a new position in shares of BioLineRx during the 2nd quarter valued at $462,000. 1.56% of the stock is currently owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.